Conclusions
Remimazolam is an effective and safe option for achieving adequate sedation during bronchoscopy, with a shorter onset time and faster neuropsychiatric recovery time than midazolam. Additionally, patient satisfaction was significantly higher in the remimazolam group than in the midazolam group, particularly in the non-biopsy group. Therefore, this drug may provide a new option for sedation during bronchoscopy.